InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

- Current share price for CU6 : $2.140

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$798 PROPELLER Trial Results 14 Feb 2023 9:22AM $0.755 $2.140 risen by 183.44%
$798 Ceasing to be a substantial holder 13 Feb 2023 4:40PM $0.755 $2.140 risen by 183.44%
$798 Diagnostic prostate cancer trial reaches recruitment target 9 Feb 2023 9:48AM $0.830 $2.140 risen by 157.83%
$798 Application for quotation of securities - CU6 2 Feb 2023 4:46PM $0.845 $2.140 risen by 153.25%
$798 Changes to Clarity Board of Directors 1 Feb 2023 10:04AM $0.860 $2.140 risen by 148.84%
$798 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2023 9:55AM $0.830 $2.140 risen by 157.83%
$798 Notification regarding unquoted securities - CU6 30 Jan 2023 12:13PM $0.865 $2.140 risen by 147.40%
$798 Positive topline results from SAR-bisPSMA diagnostic trial 14 Dec 2022 9:30AM $0.935 $2.140 risen by 128.88%
$798 Cleansing Notice 13 Dec 2022 10:27AM $0.960 $2.140 risen by 122.92%
$798 Application for quotation of securities - CU6 13 Dec 2022 10:20AM $0.960 $2.140 risen by 122.92%
$798 Change of Director's Interest Notices - Taylor and Biggin 9 Dec 2022 4:46PM $0.910 $2.140 risen by 135.16%
$798 Notification regarding unquoted securities - CU6 9 Dec 2022 11:51AM $0.935 $2.140 risen by 128.88%
$798 Clarity Corporate Presentation & Webinar 2 Dec 2022 9:43AM $0.970 $2.140 risen by 120.62%
$798 Clarity Corporate Presentation & Webinar 2 Dec 2022 9:43AM $0.970 $2.140 risen by 120.62%
$798 Results of Meeting 24 Nov 2022 11:31AM $0.920 $2.140 risen by 132.61%
$798 Managing Director's Presentation to AGM 24 Nov 2022 8:59AM $0.985 $2.140 risen by 117.26%
$798 Chairman's Address to Shareholders 24 Nov 2022 8:49AM $0.985 $2.140 risen by 117.26%
$798 ESG Report 23 Nov 2022 3:32PM $0.980 $2.140 risen by 118.37%
$798 IND approval from the FDA for theranostic SAR-Bombesin trial 21 Nov 2022 9:50AM $0.925 $2.140 risen by 131.35%
$798 Application for quotation of securities - CU6 18 Nov 2022 11:11AM $0.945 $2.140 risen by 126.46%
$798 Clarity Presentation -Bell Potter Healthcare Conference 2022 9 Nov 2022 11:32AM $0.970 $2.140 risen by 120.62%
$798 Notification regarding unquoted securities - CU6 3 Nov 2022 4:17PM $0.695 $2.140 risen by 207.91%
$798 50% recruitment reached for Phase II prostate cancer trial 2 Nov 2022 10:09AM $0.710 $2.140 risen by 201.41%
$798 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2022 3:57PM $0.700 $2.140 risen by 205.71%
$798 Corporate Presentation - Wilsons Drug and Device Conference 28 Oct 2022 1:23PM $0.640 $2.140 risen by 234.38%

376 - 400 of 511 results

Page 16 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.